Salute e Benessere
Kine Sciences Announces First Patient Dosed in the Phase 1b/2a Study in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
KINE-101 is a novel nanopeptide and a disease modifier that controls both humoral immunity and cell-mediated immune responses by activating Treg cells. KINE-101 received FDA clearance for the Phase I study on September, 2021. The study was conducted in 40 healthy individuals in five cohorts assessed over 42 days. The design included four cohorts receiving intravenously administered ascending doses of KINE-101 (10, 30, 100, and 300 mg), and a cohort that received 96.8 mg of KINE-101 subcutaneously. The Phase 1 study was completed successfully on October, 2023 demonstrating an excellent safety profile. Beyond CIDP, KINE-101 is in development for additional indications, including Inflammatory Bowel Disease, Rheumatoid Arthritis and Non-Alcoholic Steatohepatitis.
Kine Sciences was founded in 2016. It is a clinical-stage, biopharmaceutical company developing ultra small size peptides for a range of immune-mediated diseases based on functional immunomics. The company's peptides derive from a novel anti-inflammatory cytokine that targets different immune cells. Kine Sciences' approach and the ultra-small size of the peptides offers clear advantages such as a favourable pharmacokinetic vs pharmacodynamic profile, low immunogenicity, low antigenicity, low production costs and potential for oral administration. Beyond KINE-101, the company is advancing several novel candidates through preclinical studies across different indications. For more information, on the company and its pipeline visit the Kine Sciences website at http://kinesciences.com/ .
kyriakos@pharmaventures.com
+44 (0)7387 101 284
Ju Yeon Lee ,
jylee@kinesciences.com
View original content: https://www.prnewswire.co.uk/news-releases/kine-sciences-announces-first-patient-dosed-in-the-phase-1b2a-study-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-302246639.html